Dayra Therapeutics
Dayra Therapeutics manufactures peptide based medicines.
Dayra Therapeutics manufactures peptide based medicines.
Dayra Therapeutics has raised $20.0M across 1 round. Its most recent round was a Venture - Series Unknown of $20.0M in Nov 2025. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Dayra Therapeutics is featured in
Similar companies
Chirality Biosciences is a developer of chiral molecule separation technology enabling faster, safer, and side-effect-free drug production.
Bexorg provides a technology platform for central nervous system drug discovery and development.
AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.
OncoC4 is a biopharmaceutical company that engages in the discovery and development of novel biologicals for cancer treatment.
AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases.
Oligon is an emerging biotechnology company developing a novel class of multimodal RNA therapeutics.
AltrixBio is a pharmaceutical company focused on oral drug that replicates the metabolic success of bariatric surgery.
SelectION is a clinical-stage biopharmaceutical company developing novel peptide therapies for autoimmune diseases
Ollin Biosciences operates as a clinical-stage biopharmaceutical company.
Enlaza Therapeutics is a biotechnology research company.
4TEEN4 Pharmaceuticals develops innovative therapies and biomarkers for diagnosis, prediction, and treatment of Circulatory Shock.
Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.